What Is PT-141 (Bremelanotide)?
PT-141 is the development name for bremelanotide, a synthetic cyclic peptide that acts on melanocortin receptors in the nervous system. In the United States, bremelanotide is the active medicine in Vyleesi.
The US Food and Drug Administration, normally called the FDA, approved Vyleesi in 2019 for acquired, generalised hypoactive sexual desire disorder in certain premenopausal women. That is a narrow medical use. It is not a general sexual-performance medicine and is not approved for men or postmenopausal women.
Are PT-141 and bremelanotide the same?
Yes. PT-141 was the research and development code. Bremelanotide is the generic medicine name. Vyleesi is the US brand name for one FDA-approved finished product containing bremelanotide.
These names describe related levels of identity, but they are not interchangeable in every claim. Evidence for Vyleesi concerns a regulated product with a specified formulation, manufacturer, quality system and approved label. A product offered online as “PT-141” has not necessarily been assessed as equivalent.
What is bremelanotide made from?
Bremelanotide is a synthetic heptapeptide, meaning a chain containing seven amino-acid residues. Its chemical structure is written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.
Several parts of that description need translation. Nle means norleucine, an amino-acid building block used in peptide design. D-Phe is a mirror-image form of phenylalanine. Most amino acids in human proteins use the L form, so using a D form can change a peptide's shape and resistance to breakdown. “Ac” means the beginning of the chain is acetylated, a small chemical modification. “Cyclo” means part of the peptide is joined into a ring.
The ring helps hold the molecule in a shape that can activate melanocortin receptors and can make it less vulnerable to enzymes that cut peptide bonds. Bremelanotide is not testosterone, oestrogen, a steroid or a phosphodiesterase type 5 inhibitor such as sildenafil.
When was PT-141 first documented?
PT-141 grew out of research on melanotan II, another synthetic melanocortin peptide. Researchers noticed that melanocortin compounds could affect sexual responses as well as pigmentation. Palatin Technologies, Inc., a US biotechnology company developing melanocortin medicines, then developed PT-141 for sexual dysfunction.
An English-indexed paper published in 2003 described the molecule, animal findings and early studies in men. By September 2003, a Phase 2b programme in erectile dysfunction had been completed. Phase 2 studies ask whether a medicine appears to work in people with the target condition and continue safety assessment. The letter “b” usually refers to a later part of that stage used to refine the treatment approach before larger trials.
Development later moved towards female sexual desire and from an intranasal product, applied inside the nose, to a subcutaneous formulation, delivered into the fatty tissue beneath the skin. A Phase 2 dose-finding study was published in 2016. The two RECONNECT Phase 3 trials then tested the subcutaneous product in a larger population. Phase 3 trials are designed to confirm benefit and collect broader safety information before a possible approval application. The FDA approved Vyleesi in June 2019.
| Year or timeframe | Development milestone |
|---|---|
| Late 1990s to early 2000s | PT-141 was developed from melanocortin peptide research |
| 2003 | A paper described PT-141 and early findings in animals and men |
| 2012 to 2014 | The main Phase 2 dose-finding study enrolled premenopausal women |
| 2015 to 2016 | The two RECONNECT Phase 3 trials began |
| June 2019 | The FDA approved Vyleesi for a specific form of low sexual desire |
How is bremelanotide synthesised and manufactured?
Bremelanotide is manufactured by chemical peptide synthesis. It is not extracted from human brain tissue, sexual organs or animal glands.
The starting peptide materials are protected versions of norleucine, aspartic acid, histidine, D-phenylalanine, arginine, tryptophan and lysine. Manufacturers also use a solid resin, coupling chemicals, protecting-group reagents and suitable solvents. The acetyl group at the beginning of the molecule requires an acetylating material.
A common approach is solid-phase peptide synthesis, or SPPS. The first protected amino acid is fixed to resin beads. Chemists then remove one temporary protecting group and join the next amino acid in the planned order. Protecting groups stop reactive parts of the building blocks joining in the wrong place.
After the linear chain has been assembled, selected parts of the aspartic acid and lysine residues are linked to close the ring. This is called cyclisation. The remaining protecting groups are removed and the peptide is released from the resin.
The crude peptide contains the intended cyclic molecule, incomplete chains and reaction by-products. Preparative high-performance liquid chromatography, shortened to HPLC, can separate them. Mass spectrometry can confirm molecular mass, while analytical HPLC checks purity. For a licensed medicine, manufacture also includes validated controls for chemical impurities, the acetate salt form, concentration, sterility, bacterial toxins and consistency between batches.
This section describes the scientific process at a high level. It does not provide a synthesis recipe, quantities, reaction conditions, sterile filling method or instructions for preparing an injectable product.
What are melanocortin receptors?
Melanocortin receptors are proteins on the surface of certain cells. A receptor receives a chemical signal and changes how the cell behaves. Five melanocortin receptor types are known, named MC1 to MC5.
Bremelanotide activates more than one type. Its intended sexual-desire effect is thought to involve the MC4 receptor in the central nervous system, which consists of the brain and spinal cord. The exact sequence of brain signals that produces the clinical effect is not fully established.
Activation of MC1 receptors helps explain skin darkening. MC1 receptors are found on melanocytes, the cells that make the pigment melanin. This is why pigmentation is a biological effect of the same drug rather than an unrelated cosmetic reaction.
Where does bremelanotide act in the body?
Bremelanotide is described as a centrally acting medicine. Centrally acting means that its intended effect involves the central nervous system rather than only a local change in blood vessels or genital tissue.
Laboratory research points towards melanocortin signalling in parts of the brain that help coordinate motivation, reward and sexual behaviour. The hypothalamus is one region discussed in this research. It is a small part of the brain involved in appetite, hormones, body temperature and several motivated behaviours. Animal experiments also report changes in dopamine signalling. Dopamine is a neurotransmitter used by nerve cells and is involved in movement, motivation and reward.
These observations do not amount to a complete human mechanism. The FDA label states that the pathway by which bremelanotide improves HSDD is unknown. It is therefore more accurate to say that the medicine activates melanocortin receptors and is thought to influence central sexual-desire pathways than to claim that it switches desire on or corrects a known chemical imbalance.
The same receptor family is active in other systems. MC1 activity helps explain pigmentation, while central melanocortin signalling can affect blood pressure, heart rate and nausea. A receptor mechanism can therefore help explain both an intended effect and unwanted effects.
How is PT-141 different from sildenafil?
Sildenafil is a phosphodiesterase type 5 inhibitor, often shortened to a PDE5 inhibitor. It supports blood flow involved in an erection by reducing the breakdown of a signalling molecule in blood vessels.
Bremelanotide acts through melanocortin receptors in the nervous system. Its approved use concerns sexual desire and related distress in a defined group of women. It is not approved as a substitute for sildenafil or as a general erection medicine.
A small study did examine bremelanotide in men who had not responded adequately to sildenafil. Thirty-four men received bremelanotide and placebo on separate occasions while also taking sildenafil. The study reported changes in erectile responses and intercourse satisfaction. Its size and design do not establish a general approved use in men.
The research administration levels and timing from that study are not included because they are not needed to explain the result and could be mistaken for personal instructions.
What did the early studies in men actually test?
Several early trials tested PT-141 in men, but they answered narrower questions than the later Vyleesi programme.
One double-blind, placebo-controlled study examined intranasal PT-141 in 24 healthy men and 24 men with mild-to-moderate erectile dysfunction who had previously responded to sildenafil. Double-blind means neither the participants nor the researchers assessing them knew which study product had been given. Erectile response was measured with a RigiScan device, which records changes in penile circumference and rigidity over time.
The study reported more erectile activity with higher PT-141 levels than with placebo. The result was a physiological measurement made during a short laboratory visit. It did not establish improved relationships, long-term sexual function or safety with repeated use.
A separate programme examined subcutaneous PT-141 in healthy men and men who reported an inadequate response to sildenafil. It also measured erectile response under controlled conditions. These small, early studies helped show that melanocortin signalling could affect erectile physiology through a pathway different from sildenafil.
Another crossover study enrolled 19 men who described themselves as responders to sildenafil or vardenafil. In a crossover design, each person receives more than one study condition at different visits, allowing comparisons within the same participant. The study compared low-level sildenafil plus intranasal PT-141, sildenafil plus a placebo spray, and two placebos. The combined condition produced a larger measured erectile response, but 19 participants are far too few to establish a safe combination strategy.
The larger at-home trial in men who reported an inadequate response to sildenafil included 342 participants. It reported better questionnaire outcomes with intranasal bremelanotide than placebo. That study still concerned an older nasal formulation and did not lead to an approved indication for men.
These trials show why “studied in men” and “approved for men” are not the same statement. They provide a signal that justified research, but the eventual FDA application and approval concerned a different population, condition, formulation and clinical outcome.
The administration levels used in these studies are available in the source papers. They are not reproduced here because the older nasal and experimental subcutaneous products are not interchangeable with one another or with unregulated products sold as PT-141.
Why did development move away from the nasal product?
The earliest PT-141 programme used a spray applied inside the nose. Intranasal delivery can be convenient, but absorption through the nasal lining varies between people and products. Development was also affected by concern about increases in blood pressure.
The approved Vyleesi product is a subcutaneous formulation. Evidence for that product comes from studies of a specified solution and prefilled device. Results from the earlier nasal programme cannot be used to validate a nasal spray sold today, and approval of the injected product does not create approval for another route.
Route is part of a medicine's identity. It can change how much of the active ingredient reaches the circulation, how quickly it arrives, how long exposure lasts and which local reactions occur. A product containing the same named peptide but delivered in another way requires its own quality, pharmacology and clinical evidence.
What condition is Vyleesi approved to treat?
The approved condition is acquired, generalised hypoactive sexual desire disorder, normally shortened to HSDD, in premenopausal women.
“Hypoactive” means reduced activity. In HSDD, low sexual desire causes marked distress or difficulty in relationships. Acquired means the problem developed after a period of previously satisfactory desire. Generalised means it occurs across situations, types of stimulation and partners rather than only in one particular setting. Premenopausal means before menopause, when menstrual periods have permanently stopped.
The approved label also says the low desire must not be better explained by another medical or mental-health condition, relationship problems, or the effects of a medicine or substance. Diagnosis therefore involves more than deciding that desire is lower than someone would prefer.
Vyleesi is not approved to improve sexual performance. It is not approved for postmenopausal women or men.
Why is the approved indication so specific?
Sexual desire varies between people and across periods of life. A lower level is not automatically a disorder. The HSDD diagnosis used in the trials required both persistently low desire and distress about it. It also required clinicians to consider whether another condition, a medicine, substance use or relationship problem offered a better explanation.
The word acquired excluded people whose low desire had always been present. Generalised excluded problems limited to one partner, situation or type of stimulation. Premenopausal defined the life stage tested in the pivotal trials. These criteria produced a more consistent research population and now form part of the approved boundary.
The pivotal studies did not establish benefit in men, postmenopausal women, people whose symptoms were caused by another medicine, or people seeking better sexual performance without HSDD. A biological theory about melanocortin receptors cannot fill those evidence gaps.
The trial population also affects how broadly the findings can be applied. Participants had a mean age of 39, 86% were white and 12% were Black. Their average relationship duration was 12 years and their HSDD had lasted about four years. Most were in US sites. The trials therefore provide stronger evidence for people resembling that population than for groups who were scarcely represented.
What did the Phase 2 trial find?
The Phase 2 study was a dose-finding trial, meaning it compared several administration levels to select one for later research. It included 327 premenopausal women in the efficacy analysis and lasted 12 weeks.
Participants were randomly assigned to placebo or one of three bremelanotide levels: 0.75, 1.25 or 1.75 milligrams. Random assignment means chance determined the group, reducing the risk that the groups differed systematically before treatment. A placebo is an inactive comparison designed to resemble the study treatment.
For the pooled 1.25 and 1.75 milligram groups, satisfying sexual events increased by an average of 0.7 per month, compared with 0.2 with placebo. Questionnaire scores measuring sexual function and related distress also improved more with bremelanotide. Nausea, flushing and headache were among the common adverse events.
These levels belong to a controlled study and are reported to explain how the approved programme developed. They are not dosage recommendations.
What were the RECONNECT trials?
RECONNECT was the name for two similarly designed Phase 3 trials, called Study 301 and Study 302. Together they enrolled 1,267 premenopausal women with acquired, generalised HSDD. Palatin Technologies, Inc. and AMAG Pharmaceuticals, Inc., a US pharmaceutical company that later held commercial rights, funded the research.
Participants were randomly assigned to bremelanotide 1.75 milligrams or placebo for 24 weeks. The trials were double-blind, meaning neither participants nor the main study staff knew the assignment during the comparison period. This helps reduce differences in expectations and assessment.
The studies had two main outcomes. One was the desire section of the Female Sexual Function Index, a questionnaire in which higher scores indicate greater desire. The other was a specific item from the Female Sexual Distress Scale, asking how often the participant felt bothered by low desire. Lower distress scores indicate improvement.
Both outcomes improved by a statistically greater amount with bremelanotide than with placebo. “Statistically greater” means the observed difference was unlikely to be explained by chance under the study analysis. It does not say how large or important the average difference felt to each person.
The trials did not find a significant difference in the change in satisfying sexual events, another outcome collected during the studies. The evidence therefore supports a modest average improvement in desire and distress scores, not a guaranteed increase in sexual activity or satisfaction.
How large were the Phase 3 changes?
The size of a change matters as well as whether it passes a statistical test.
In Study 301, the average desire score increased by 0.5 points with bremelanotide and 0.2 points with placebo on a scale running from 1.2 to 6.0. In Study 302, the changes were 0.6 and 0.2 points. The difference attributable to treatment was therefore about 0.3 to 0.4 points on average.
For the distress question, scored from 0 to 4, the average change was a reduction of 0.7 points with bremelanotide and 0.4 points with placebo in both studies. The average difference was 0.3 points. Lower scores indicate less frequent distress about low desire.
The published integrated analysis expressed these as treatment differences of 0.35 points for desire and 0.33 points for distress. An average combines people with larger changes, little change and no improvement. It cannot tell an individual what they would experience.
The studies also defined responder thresholds intended to represent a noticeable change. The FDA examined these alongside completion rates because more participants left the bremelanotide groups early. In Study 301, 40% of the bremelanotide group and 13% of the placebo group did not complete the 24-week period. In Study 302, the figures were 39% and 25%.
Attrition is the loss of participants before a trial ends. High and unequal attrition can make a result harder to interpret, especially when side effects influence who remains. The FDA still judged the total evidence sufficient for the narrow indication, but the missing data and modest average differences remain part of an accurate account.
The satisfying-sexual-event outcome did not support a benefit. The average change was essentially zero in both treatment groups in the FDA tables. This is why the approval should be described as an improvement in reported desire and related distress, not as proof of more sexual activity.
What do patient-reported outcomes mean here?
There is no blood test or scan that directly measures sexual desire. The RECONNECT trials therefore used patient-reported outcomes, meaning structured answers given by the participants themselves.
This does not make the outcomes unscientific. Desire and distress are personal experiences, so asking the person is necessary. Validated questionnaires use standard wording and scoring so that answers can be compared consistently across participants and time.
However, a questionnaire score needs context. Statistical significance asks whether a group difference is unlikely to be a chance result under the analysis. Clinical importance asks whether the size of that difference is meaningful in daily life. The two questions are related but not identical.
The double-blind placebo design helped reduce the influence of expectations. It could not remove every source of bias. Nausea and flushing were much more common with active treatment, so some participants may have guessed their assignment. The trials also measured an average treatment effect across a selected population rather than guaranteeing benefit for every participant.
The strongest conclusion is that bremelanotide produced a small average improvement on two relevant self-report measures in the studied population. The evidence does not support a promise of a particular personal response.
What did longer follow-up show?
Women who completed the controlled trials could enter a 52-week open-label extension. Open-label means participants and researchers knew that the active medicine was being used.
Of 856 eligible women, 684 entered and 272 completed the extension. The authors reported maintained questionnaire improvements and no new broad safety pattern. The large number who did not complete the extension makes the result harder to interpret because people who tolerate or value a treatment may be more likely to remain.
One participant developed acute hepatitis during longer follow-up. Hepatitis means inflammation of the liver. The event resolved after treatment stopped, but it is part of the full safety record and should not be removed from discussion simply because it was rare.
How does the body handle bremelanotide?
Pharmacokinetics describes what the body does to a medicine, including absorption, distribution, breakdown and removal.
After the approved subcutaneous product enters the circulation, bremelanotide reaches its highest average blood concentration in about one hour. Its mean terminal half-life is about 2.7 hours. Half-life is the time taken for the measured concentration to fall by half during the final elimination phase. It does not mean every biological effect ends after that period.
The peptide is broken down mainly by hydrolysis of its amide bonds. Hydrolysis is a chemical process that uses water to split the links between amino acids. In a radiolabel study, about 64.8% of measured radioactivity was recovered in urine and 22.8% in faeces. Radioactivity in this type of study traces the medicine and its breakdown products rather than implying that the medicine itself is radioactive in ordinary use.
Exposure was higher in people with reduced kidney or liver function. Exposure means the total concentration measured in blood over time. Severe liver impairment was not studied. These findings are one reason a regulated product has prescribing information for specific populations rather than a single statement that the peptide is safe.
What are the main safety warnings?
The approved label lists several important limits.
Bremelanotide temporarily increases blood pressure and reduces heart rate after each administration. Blood pressure is the force of blood against artery walls. Heart rate is the number of heartbeats per minute. The average maximum changes in clinical studies were an increase of about 6 millimetres of mercury in systolic pressure, the top number, and 3 millimetres in diastolic pressure, the bottom number, with a fall of about 5 beats per minute. The effects generally returned towards baseline within about 12 hours.
The product is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. Contraindicated means it should not be used because the risk is considered too high. Cardiovascular disease affects the heart or blood vessels.
Nausea occurred in about 40% of participants receiving bremelanotide in the controlled trials. Around 13% required an anti-nausea medicine and 8% stopped treatment because of nausea. Other common reactions included flushing, injection-site reactions, headache and vomiting.
Focal hyperpigmentation means patches of skin become darker. It was reported in about 1% of patients using the product up to eight times per month, and it did not always resolve after stopping. People with darker skin may be more likely to develop this effect.
Bremelanotide can slow gastric emptying, meaning food and medicines leave the stomach more slowly. This can affect the absorption of some oral medicines. The clinical importance depends on the medicine, particularly when rapid absorption is important.
How common were adverse reactions in the controlled trials?
The pooled FDA data included 627 participants assigned to bremelanotide and 620 assigned to placebo.
Nausea was reported by 40.0% of the bremelanotide group and 1.3% of the placebo group. Flushing affected 20.3% and 0.3%, injection-site reactions 13.2% and 8.4%, headache 11.3% and 1.9%, and vomiting 4.8% and 0.2%. Injection-site reactions included pain, redness, bruising, itching and altered sensation around the site.
The high nausea figure was driven partly by the first exposure. Nausea began within about one hour on average and lasted about two hours. It affected 21% after the first bremelanotide administration and fell to about 3% after later administrations. Even so, 13% used an anti-nausea medicine and 8% left the trials because of nausea.
Overall, 18% of bremelanotide participants stopped the controlled trials because of an adverse reaction, compared with 2% receiving placebo. Serious adverse events were reported by 1.1% and 0.5%, respectively. These numbers give a fuller picture than saying that most events were mild or moderate.
A dedicated randomised blood-pressure study used monitoring over a full day rather than relying only on measurements taken in a clinic. It confirmed a small average increase in daytime blood pressure and a decrease in heart rate. An average can hide larger individual responses, which is why the approved contraindications and cardiovascular assessment remain important.
What other safety limits are easy to miss?
Bremelanotide slows stomach emptying. This may delay or reduce the absorption of oral medicines. The FDA label gives particular attention to oral naltrexone, a medicine used in the treatment of alcohol or opioid dependence, because reduced exposure could cause the treatment to fail. The label also discusses medicines that need to reach a threshold concentration quickly, including some antibiotics and pain medicines.
Pregnancy evidence is limited. Only seven pregnancies were reported across the clinical programme, too few to determine human risk. Animal studies raised concern about foetal harm at exposures above the human level, so the label advises stopping if pregnancy is suspected and using effective contraception during treatment. These are product-label facts, not reproductive advice from this guide.
There is no adequate information on bremelanotide in human milk or its effect on a breastfed infant. The product was not studied in children. Older adults were not part of the approved premenopausal population.
The single acute hepatitis case in the extension study did not establish a recurring liver-safety pattern, but another cause was not found and the medicine's role could not be excluded. A rare report should neither be presented as proof of a common risk nor left out of the record.
These limits matter when discussing unregulated PT-141 products. A purity claim does not provide the clinical screening, contraindication review, interaction assessment or adverse-event reporting that surrounds an approved medicine.
Does FDA approval make every PT-141 product approved?
No. The FDA approved Vyleesi as a particular finished medicine for a particular group and purpose. The approval rests on its formulation, manufacturing controls, clinical evidence and labelling.
A compounded or research product bearing the names PT-141 or bremelanotide is not automatically the same approved product. Compounding means a pharmacy prepares a medicine for an individual need under specific legal conditions. Compounded medicines are not FDA approved before sale in the way that Vyleesi was.
Products from unregulated online sellers create further uncertainty about identity, strength, purity, sterility and storage history.
What benefits are claimed, and what does the evidence support?
| Claim | What the evidence supports |
|---|---|
| Treats low sexual desire | Approved only for acquired, generalised HSDD in certain premenopausal women |
| Increases satisfying sexual events | The Phase 3 trials did not show a significant improvement in this outcome |
| Works for men | Small erectile-function studies exist, but there is no FDA-approved use in men |
| Improves sexual performance | The approved label specifically says it is not indicated to enhance performance |
| Raises testosterone | It is not a testosterone treatment and this is not its established mechanism |
| Works like sildenafil | No. It acts through melanocortin receptors rather than the PDE5 blood-vessel pathway |
| Is safe because it is approved | Approval establishes a defined benefit-risk judgement for one use, not freedom from side effects |
Frequently asked questions
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development name and bremelanotide is the generic medicine name.
Is PT-141 a peptide?
Yes. It is a synthetic cyclic peptide containing seven amino-acid residues.
Is PT-141 FDA approved?
The FDA-approved product Vyleesi contains bremelanotide. Approval is limited to acquired, generalised HSDD in certain premenopausal women and does not extend to every product sold as PT-141.
Does PT-141 work for men?
Small studies examined erectile responses in men, but bremelanotide is not FDA approved for men and the evidence does not establish a general male treatment.
Does PT-141 increase testosterone?
It is not testosterone and its approved action is not based on raising testosterone.
Is PT-141 the same as Melanotan II?
No. Bremelanotide was developed from melanocortin peptide research related to Melanotan II, but it is a separate molecule and medicine.
What are the common side effects?
Nausea, flushing, injection-site reactions and headache were common in clinical trials. Temporary blood-pressure changes and darker skin patches are important warnings.
How was PT-141 tested in the Phase 3 trials?
The RECONNECT trials compared bremelanotide with inactive placebo over 24 weeks in 1,267 premenopausal women with acquired, generalised HSDD.
When was bremelanotide approved?
The FDA approved Vyleesi in June 2019.
How is bremelanotide made?
It is chemically assembled from protected amino-acid building blocks, formed into a ring, purified and tested. Licensed manufacture adds strict controls for product quality and sterility.
Can PT-141 be combined with other medicines?
This guide provides no combination advice. Bremelanotide can affect blood pressure and the absorption of some oral medicines, so interactions require professional assessment.
What the evidence supports today
Bremelanotide is unusual among peptides discussed online because one finished product has passed a full FDA review. Its structure, manufacturing controls, clinical results and main risks are documented in public regulatory material.
The evidence should still be described accurately. The approval covers a specific diagnosis in premenopausal women. The average trial improvements were in desire and distress questionnaire scores, while satisfying sexual events did not improve significantly. Nausea was common and cardiovascular, pigmentation and medicine-absorption warnings remain important. The Research Methodology guide explains why approved use, study outcomes and evidence outside the approved population must be considered separately.
The correct conclusion is not that PT-141 is an unproven peptide in every context, nor that it is a general sexual-performance treatment. Bremelanotide is an approved medicine within a narrow boundary, and claims outside that boundary require their own evidence.
Sources
Research reviewed through September 2026.